Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Molecular and Clinical Oncology|July 15, 2015
Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinomaLeonardo Gomes DA Fonseca, Romualdo Barroso-Sousa, Afonso DA Silva Alves Bento, et al.
Oncotarget|October 7, 2015
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practiceLuís Felipe Campesato, Romualdo Barroso-Sousa, Leandro Jimenez, et al.
Breast (Edinburgh, Scotland)|July 3, 2026
Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancerMariana Carvalho Gouveia, Pedro José Galvão Freire, Caio Guilherme Souza Prado, et al.
Breast Cancer Research and Treatment|May 5, 2026
Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?Lis Victória Ravani, Seth A Wander, Marleen Kok, et al.
Genes|July 27, 2024
<i>TP53</i> p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest BrazilTatiana Strava Corrêa, Paula Fontes Asprino, Eduarda Sabá Cordeiro de Oliveira, et al.
Breast Care (Basel, Switzerland)|November 19, 2014
Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experienceLeonardo Gomes da Fonseca, Debora de Melo Gagliato, Tiago K Takahashi, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|January 24, 2015
Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patientsRomualdo Barroso-Sousa, Rodrigo R Munhoz, Milena P Mak, et al.
Breast (Edinburgh, Scotland)|August 5, 2025
Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysisGabriel Berlingieri Polho, Yumi Ricucci Shinkado, Leticia Kimie Murazawa, et al.
Ecancermedicalscience|February 16, 2026
Neutrophil-to-lymphocyte ratio predicts long-term survival in early triple negative breast cancer treated with neoadjuvant chemotherapyGabriel Berlingieri Polho, Leticia Kimie Murazawa, Vinicius Vitor Oliveira, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast CancerCarlos Wagner S Wanderley, Daniel E Michaud, Kenichi Shimada, et al.
Pageof 10